The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2025 | The value of whole genome sequencing in multiple myeloma
Mehmet Samur, PhD, Dana-Farber Cancer Institute, Boston, MA, comments on the value of whole genome sequencing (WGS) in multiple myeloma (MM), highlighting its role in improving the understanding of disease biology, enhancing risk stratification, and identifying new targets. Dr Samur emphasizes the importance of deciphering non-coding genetic alterations and combining available information to better understand the disease. This interview took place at the 11th World Congress on Controversies in Multiple Myeloma (COMy) congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The key points from the whole genome is that now we have new risk stratification, now we have ways to understand the disease better. What else we can do beyond it? And whole genome is obviously one place where we learn thousands and thousands of new things, where we find thousands of alterations for a given patient. Beyond the usual suspects, how we can use this very diverse set of information to gain more insights about the additional risk stratification and about the disease biology...
The key points from the whole genome is that now we have new risk stratification, now we have ways to understand the disease better. What else we can do beyond it? And whole genome is obviously one place where we learn thousands and thousands of new things, where we find thousands of alterations for a given patient. Beyond the usual suspects, how we can use this very diverse set of information to gain more insights about the additional risk stratification and about the disease biology. Obviously, these thousands of changes, most of them occur in the non-coding part of the genome, which we think still hides a lot of information from us. By using whole genome sequencing, we are hoping that we will be able to decode some of these and then get more insights about the disease, maybe find new targets, maybe find new stratification factors and learn beyond what we have today. All the whole genome sequencing studies from precursor disease to newly diagnosed to relapsed myeloma show that accumulated DNA alterations or accumulated damage is one of the factors that we need to focus on. We are seeing from other studies, and our studies, that the mutational signatures, the mutational patterns is one factor. And I think it’s up to us how we can combine all this information next and learn more about multiple myeloma.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
